RESUMEN
Clinical application of anticancer agents has been often hampered by toxicity against normal cells, so the achievement of their cancer-specific action is still one of the major challenges to be addressed. Previously, we reported that arsenic trioxide (As2O3) could be a promising new drug against not only leukemia but also solid tumors. The cytotoxicity of As2O3 occurred through the generation of reactive oxygen species (ROS), thus inhibiting radical scavenging systems would enhance the therapeutic efficacy of As2O3 provided that normal cells were relatively resistant to such a measure. Here, we report that the combination therapy of As2O3 with L-buthionine-sulfoximine (BSO), which inhibits a critical step in glutathione synthesis, effectively enhanced in vitro growth inhibition effect of As2O3 on all 11 investigated cell lines arising from prostate, breast, lung, colon, cervix, bladder, and kidney cancers, compared with As2O3 treatment alone. Furthermore, this combination enhanced cytotoxicity to cell lines from prostate cancer with less toxicity to those from normal prostate. In vitro cytotoxic assay using ROS-related compounds demonstrated that hydrogen peroxide (H2O2) is a major cytotoxic mediator among ROS molecules. Biochemical analysis showed that combined use of As2O3 and BSO blocked H2O2-scavenging systems including glutathione, catalase, and glutathione peroxidase, and that the degree of this blockade was well correlated with intracellular ROS levels and sensitivity to this treatment. Finally, the effectiveness of the combination therapy of As2O3 with BSO was demonstrated with an orthotopic model of prostate cancer metastasis. We propose that the combination therapy of As2O3 with BSO is a valid means of blockade of H2O2-scavenging system, and that the combination of a ROS-generating agent with an inhibitor of major scavenging systems is effective in terms of both efficacy and selectivity. Furthermore, because the effective doses of both compounds are within clinically achievable range, this report will lead to immediate benefit for the development of a new cancer therapy.
Asunto(s)
Antineoplásicos/farmacología , Arsenicales/farmacología , Butionina Sulfoximina/farmacología , Neoplasias/tratamiento farmacológico , Óxidos/farmacología , Animales , Apoptosis/efectos de los fármacos , Trióxido de Arsénico , División Celular/efectos de los fármacos , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Resistencia a Antineoplásicos , Quimioterapia Combinada , Femenino , Glutatión/análisis , Glutatión/metabolismo , Células HeLa , Humanos , Peróxido de Hidrógeno/metabolismo , Masculino , Ratones , Metástasis de la Neoplasia/patología , Metástasis de la Neoplasia/prevención & control , Trasplante de Neoplasias , Neoplasias/patología , Neoplasias de la Próstata/tratamiento farmacológico , Especies Reactivas de Oxígeno/análisis , Especies Reactivas de Oxígeno/metabolismo , Trasplante Heterólogo , Ensayos Antitumor por Modelo de XenoinjertoAsunto(s)
Enfermedad de Machado-Joseph/genética , Proteínas del Tejido Nervioso/genética , Expansión de Repetición de Trinucleótido/genética , Secuencia de Aminoácidos , Animales , Ataxina-3 , Secuencia de Bases , Modelos Animales de Enfermedad , Humanos , Enfermedad de Machado-Joseph/patología , Datos de Secuencia Molecular , Mutación , Proteínas Nucleares , Proteínas RepresorasRESUMEN
We have successfully generated a Drosophila model of human polyglutamine (polyQ) diseases by the targeted expression of expanded-polyQ (ex-polyQ) in the Drosophila compound eye. The resulting eye degeneration is progressive and ex-polyQ dosage- and ex-polyQ length-dependent. Furthermore, intergenerational changes in repeat length were observed in homozygotes, with concomitant changes in the levels of degeneration. Through genetic screening, using this fly model, we identified loss-of-function mutants of the ter94 gene that encodes the Drosophila homolog of VCP/CDC48, a member of the AAA+ class of the ATPase protein family, as dominant suppressors. The suppressive effects of the ter94 mutants on ex-polyQ-induced neurodegeneration correlated well with the degrees of loss-of-function, but appeared not to result from the inhibition of ex-polyQ aggregate formation. In the ex-polyQ-expressing cells of the late pupa, an upregulation of ter94 expression was observed prior to cell death. Co-expression of ter94 with ex-polyQ severely enhanced eye degeneration. Interestingly, when ter94 was overexpressed in the eye by increasing the transgene copies, severe eye degeneration was induced. Furthermore, genetical studies revealed that ter94 was not involved in grim-, reaper-, hid-, ced4-, or p53-induced cell death pathways. From these observations, we propose that VCP is a novel cell death effector molecule in ex-polyQ-induced neurodegeneration, where the amount of VCP is critical. Control of VCP expression may thus be a potential therapeutic target in ex-polyQ-induced neurodegeneration.
Asunto(s)
Apoptosis/fisiología , Proteínas de Ciclo Celular/metabolismo , Proteínas de Drosophila/metabolismo , Drosophila melanogaster/fisiología , Enfermedades Neurodegenerativas/metabolismo , Péptidos , Repeticiones de Trinucleótidos/genética , Adenosina Trifosfatasas , Animales , Apoptosis/genética , Proteínas de Ciclo Celular/química , Modelos Animales de Enfermedad , Drosophila melanogaster/genética , Ojo/crecimiento & desarrollo , Ojo/fisiopatología , Mutación , Enfermedades Neurodegenerativas/inducido químicamente , Enfermedades Neurodegenerativas/genética , Fenotipo , Repeticiones de Trinucleótidos/fisiología , Proteína que Contiene ValosinaRESUMEN
Neuronal cell death, abnormal protein aggregates, and cytoplasmic vacuolization are major pathologies observed in many neurodegenerative disorders such as the polyglutamine (polyQ) diseases, prion disease, Alzheimer disease, and the Lewy body diseases, suggesting common mechanisms underlying neurodegeneration. Here, we have identified VCP/p97, a member of the AAA+ family of ATPase proteins, as a polyQ-interacting protein in vitro and in vivo, and report on its characterization. Endogenous VCP co-localized with expanded polyQ (ex-polyQ) aggregates in cultured cells expressing ex-polyQ, with nuclear inclusions in Huntington disease patient brains, and with Lewy bodies in patient samples. Moreover, the expression of VCP mutants with mutations in the 2nd ATP binding domain created cytoplasmic vacuoles, followed by cell death. Very similar vacuoles were also induced by ex-polyQ expression or proteasome inhibitor treatment. These results suggest that VCP functions not only as a recognition factor for abnormally folded proteins but also as a pathological effector for several neurodegenerative phenotypes. VCP may thus be an ideal molecular target for the treatment of neurodegenerative disorders.
Asunto(s)
Proteínas de Ciclo Celular/fisiología , Muerte Celular , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/patología , Neuronas/citología , Vacuolas/ultraestructura , Adenosina Trifosfatasas , Animales , Proteínas de Ciclo Celular/genética , Enfermedad de Huntington/etiología , Enfermedad de Huntington/metabolismo , Enfermedad de Huntington/patología , Cuerpos de Inclusión/metabolismo , Mutación , Enfermedades Neurodegenerativas/metabolismo , Neuronas/metabolismo , Neuronas/ultraestructura , Células PC12 , Péptidos/metabolismo , Fenotipo , Ratas , Proteína que Contiene ValosinaRESUMEN
BACKGROUND: Polyglutamine expansion in protein is responsible for several inherited neuro-degenerative diseases. The expansion has toxic effects on neural cells as well as results in forming aggregates. Using yeast, we examined the initial process of polyglutamine aggregate formation in vivo. RESULTS: Following expression, polyglutamine tracts were of a soluble form during a lag period, and then formed insoluble complexes. The lag was prolonged and the formation of insoluble complex became slower by decreasing the number of polyglutamine tracts and by a treatment with guanidine hydrochloride. Gel filtration analysis revealed that the soluble polyglutamine existed in a small form. Formation of polyglutamine aggregates appeared to follow similar kinetics reported in the in vitro studies, where polyglutamine tracts self-aggregate in a length-, concentration- and time-dependent manner. However, in vivo, Hsp104 was required for the conversion from a soluble to an insoluble state. Without Hsp104, polyglutamine tracts tended to remain in a small soluble form, prolonging the lag. Moreover, the dependency on Hsp104 for aggregate formation was strong with the short polyglutamine tract, and decreased with the long polyglutamine tract. CONCLUSION: For polyglutamine aggregate formation, a balance of parameters including the length of the polyglutamine tract, Hsp104, and level of polyglutamine expression determined its efficiency.
Asunto(s)
Proteínas Fúngicas/metabolismo , Proteínas de Choque Térmico/metabolismo , Péptidos/metabolismo , Proteínas de Saccharomyces cerevisiae , Secuencia de Aminoácidos , Secuencia de Bases , Electroforesis en Gel Bidimensional/métodos , Técnica del Anticuerpo Fluorescente , Proteínas Fúngicas/genética , Eliminación de Gen , Guanidina/farmacología , Proteínas de Choque Térmico/efectos de los fármacos , Proteínas de Choque Térmico/genética , Datos de Secuencia Molecular , Péptidos/química , Péptidos/genética , Regiones Promotoras Genéticas , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , SolubilidadAsunto(s)
Enfermedad de Machado-Joseph/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Neuronas/metabolismo , Secuencia de Aminoácidos/fisiología , Animales , Ataxina-3 , Técnicas de Cultivo de Célula , Clonación Molecular , Modelos Animales de Enfermedad , Proteínas Fluorescentes Verdes , Humanos , Indicadores y Reactivos/farmacocinética , Proteínas Luminiscentes/farmacocinética , Enfermedad de Machado-Joseph/fisiopatología , Proteínas del Tejido Nervioso/genética , Neuronas/patología , Proteínas Nucleares , Células PC12/metabolismo , Células PC12/patología , Péptidos/genética , Péptidos/metabolismo , Ratas , Proteínas Represoras , Expansión de Repetición de Trinucleótido/fisiologíaRESUMEN
Arsenic trioxide (As2O3) induces clinical remission of patients with acute promyelocytic leukemia. As a novel anticancer agent for treatment of solid cancers, As2O3 is promising, but no in vivo experimental investigations of its efficacy on solid cancers have been done at clinically obtained concentrations. In addition, the cell death mechanism of As2O3 has yet to be clarified, especially in solid cancers. In this study, human androgen-independent prostate cancer cell lines, PC-3, DU-145, and TSU-PR1 were examined as cellular models for As2O3 treatment, and As2O3-induced cell death and inhibition of cell growth and colony formation were evaluated. The involvement of p38, c-Jun NH2-terminal kinase (JNK), caspase-3, and reactive oxygen species (ROS) were investigated in As2O3-induced cell death. Finally, As2O3 was administered to severe combined immunodeficient mice inoculated orthotopically with PC-3 cells to estimate in vivo efficacy. In all three of the cell lines, at high concentrations, As2O3 induced apoptosis and, at low concentrations, growth inhibition. As2O3 activated p38, JNK, and caspase-3 dose dependently. Treatment with the p38 inhibitor and over-expression of dominant-negative JNK did not guard against As2O3-induced cell death. In contrast with partial protection by the caspase-3 inhibitor, the antioxidant N-acetyl-L-cysteine gave marked protection from As2O3-induced apoptosis and eliminated the activation of p38, JNK, and caspase-3, and the generation of ROS. The orthotopic murine metastasis model showed in vivo tumor growth inhibition in orthotopic and metastatic lesions with no signs of toxicity. This study establishes that As2O3 provides a novel, safe approach for treatment of androgen-independent prostate cancer. Generation of ROS as a therapeutic target for the potentiation of As2O3-induced apoptosis also was shown.
Asunto(s)
Antineoplásicos/farmacología , Arsenicales/farmacología , División Celular/efectos de los fármacos , Proteínas Quinasas JNK Activadas por Mitógenos , Metástasis de la Neoplasia/prevención & control , Óxidos/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Andrógenos/fisiología , Animales , Apoptosis/efectos de los fármacos , Trióxido de Arsénico , Caspasas/metabolismo , Muerte Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Activación Enzimática/efectos de los fármacos , Humanos , MAP Quinasa Quinasa 4 , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones SCID , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Metástasis de la Neoplasia/patología , Trasplante de Neoplasias , Células Madre Neoplásicas/efectos de los fármacos , Neoplasias de la Próstata/patología , Especies Reactivas de Oxígeno/metabolismo , Trasplante Heterólogo , Células Tumorales Cultivadas , Ensayo de Tumor de Célula Madre , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas Quinasas p38 Activadas por MitógenosRESUMEN
BACKGROUND: An in vivo spontaneous metastatic model using androgen-sensitive prostate cancer cells is needed to the better understanding of prostate cancer progression. Orthotopically inoculated LNCaP cells to SCID mice manifests metastases, but it takes no less than 12 weeks to detect them by conventional methods. METHODS: The green fluorescent protein (GFP) gene was introduced into LNCaP cells by conventional lipofection technique. Biological characteristics of a subline (LNCaP-GFP) that expressed GFP at high level were compared to those of the parental cells. LNCaP-GFP cells were orthotopically inoculated to the SCID mouse, and metastases to distant organs were chronologically examined under fluorescence microscopy. RESULTS: There was no difference in growth rates and androgen-responsiveness in vitro between LNCaP-GFP and LNCaP cells. LNCaP-GFP cells inoculated to SCID mice produced prostate specific antigen. Histopathological examination at 12 weeks after inoculation of LNCaP-GFP revealed that metastases were identified as the inoculation of LNCaP cells. Colonies consisting of a few LNCaP-GFP cells, however, were detected in the lung under fluorescence microscopy as early as 4 weeks after inoculation. CONCLUSIONS: Orthotopic inoculation of LNCaP-GFP to SCID mice may provide a useful tool to investigate the molecular mechanism of progression, in particular the early stage of metastasis, of androgen-sensitive prostate cancer cells.
Asunto(s)
Andrógenos/fisiología , Proteínas Luminiscentes/biosíntesis , Neoplasias Pulmonares/secundario , Neoplasias Hormono-Dependientes/secundario , Neoplasias de la Próstata/patología , Células Tumorales Cultivadas/patología , Animales , División Celular/fisiología , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/genética , Neoplasias Pulmonares/diagnóstico , Metástasis Linfática , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones SCID , Microscopía Fluorescente , Trasplante de Neoplasias , Neoplasias Hormono-Dependientes/diagnóstico , Neoplasias Hormono-Dependientes/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , TransfecciónAsunto(s)
Diseño de Fármacos , Enfermedades Neurodegenerativas/genética , Enfermedad de Alzheimer/genética , Esclerosis Amiotrófica Lateral/genética , Animales , Humanos , Enfermedad de Parkinson/genética , Péptidos/metabolismo , Enfermedades por Prión/genética , Expansión de Repetición de Trinucleótido/genéticaRESUMEN
BACKGROUND: A novel class of inherited human neurodegenerations is now known to be caused by expanded CAG repeats encoding polyglutamines. Polyglutamine-containing protein fragments have been shown to accumulate as aggregates in the nucleus and in the cytoplasm, and to induce cell death when expressed in cultured cells, leading to the proposal that polyglutamine aggregation is an important step in the pathogenesis. Supporting this, nuclear inclusions containing expanded polyglutamines have been identified in neurones from the brains of patients and in neurones from transgenic mouse models of this class of neural disorders. RESULTS: We analysed the consequences of polyglutamine expression in PC12 neuronal cells. Activated SEK1 accumulated with nuclear but not cytoplasmic polyglutamine aggregations, which consequently triggers cell death. Cell death induced by polyglutamine expression was inhibited by a dominant-negative SEK1 (DN-SEK1), but not by DN-SEK1 tagged with a nuclear export signal. Steady state SEK1 expression itself was enhanced two to three-fold. Nuclearly aggregated polyglutamines, which were identified in PML bodies, co-localized with not only activated SEK1 but also activated c-Jun. We also observed that nuclear inclusion-positive neurones from brains with Huntington's disease expressed SEK1. CONCLUSIONS: This study provides molecular links between the neurodegeneration observed in polyglutamine diseases, cell death signalling kinase cascades and nuclear subdomains related to cell death. We propose that the nuclear PML bodies containing polyglutamine aggregates activate the SEK1-JNK kinase cascade, resulting in the transduction of a death signal.
Asunto(s)
Muerte Celular/fisiología , Núcleo Celular/metabolismo , MAP Quinasa Quinasa 4 , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo , Neuronas/fisiología , Animales , Encéfalo/fisiopatología , Núcleo Celular/ultraestructura , Citoplasma/metabolismo , Activación Enzimática , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/análisis , Proteínas Luminiscentes/genética , Ratones , Ratones Transgénicos , Quinasas de Proteína Quinasa Activadas por Mitógenos/genética , Degeneración Nerviosa/genética , Neuronas/citología , Células PC12 , Péptidos/química , Péptidos/genética , Ratas , Transfección , Repeticiones de Trinucleótidos , Ubiquitinas/metabolismoRESUMEN
Molecular genetic analyses have elucidated a class of inherited neurodegenerative disorders caused by expanded CAG repeats encoding polyglutamines (e.g. Huntington disease and Machado-Joseph disease). Proteins containing expanded polyglutamine repeats appear to precipitate by self-aggregation and, as a result, produce a core disease-related phenotype: neuronal cell death or degeneration. In other neurodegenerative disorders, such as Alzheimer disease, prion disease, Parkinson disease and amyotrophic lateral sclerosis, precipitation of abnormal proteins is also now considered to play a key role. These observations might lead to the elucidation of universal mechanisms for neurodegeneration and to effective treatments for many neurodegenerative disorders.
Asunto(s)
Enfermedades Neurodegenerativas/etiología , Péptidos/metabolismo , Proteínas/metabolismo , Precipitación Química , Humanos , Cuerpos de Inclusión , Enfermedades Neurodegenerativas/metabolismo , Proteínas/química , Repeticiones de TrinucleótidosRESUMEN
We investigated the feasibility of an inducible apoptosis system to regulate cells genetically engineered for ectopic cytokine production. In a previous study, cDNA encoding the ligand-binding domain of the rat estrogen receptor was fused to the sequence for murine Fas transmembrane and cytoplasmic regions, and expression of the fusion protein (MfasER) in L929 fibroblasts resulted in estrogen-dependent apoptosis. We applied this MfasER/estrogen strategy to apoptosis-mediated regulation of cytokine production, using the human granulocyte colony-stimulating factor (G-CSF) as a model. Upon estrogen treatment, the G-CSF producers expressing MfasER showed an apoptotic phenotype and died in several hours, with termination of G-CSF production. This estrogen-induced apoptosis was not influenced by whether the target cells were proliferating or resting, unlike a conventional suicide system involving the herpes simplex virus 1 thymidine kinase (HSVtk). That is, estrogen induced prompt and extensive apoptosis in the resting cells which expressed MfasER, while ganciclovir treatment induced only partial reduction of the resting cells which expressed HSVtk. These results imply the feasibility of apoptosis-mediated regulation of cytokine production by genetically modified cells for supplement gene therapy.
Asunto(s)
Apoptosis , Ingeniería Genética , Factor Estimulante de Colonias de Granulocitos/biosíntesis , Animales , Línea Celular , Estrógenos/uso terapéutico , Fibroblastos/metabolismo , Humanos , Ratones , Ratas , Receptores de Estrógenos/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Receptor fas/genéticaRESUMEN
Several cancer gene therapy strategies involve suicide genes to kill the neoplasm, or to regulate effector cells such as lymphocytes. We have developed an inducible apoptosis system with a Fas-estrogen receptor fusion protein (MfasER) for rapid elimination of transduced cells. In the present study, we further improved this molecular switch for estrogen-inducible apoptosis to overcome concerns with the wild-type estrogen receptor and its natural ligand, 17beta-estradiol (E2). The ligand-binding domain of MfasER was replaced with that of a mutant estrogen receptor which is unable to bind estrogen yet retains affinity for a synthetic ligand, 4-hydroxytamoxifen (Tm). The resultant fusion protein (MfasTmR) and MfasER were expressed in L929 cells for examination of their ligand specificities. Tm induced apoptosis in MfasTmR-expressing cells (L929MfasTmR) at 10(-8) M or higher concentrations, but induced no apoptosis in MfasER-expressing cells (L929MfasER) at up to 10(-6) M. On the other hand, E2 induced apoptosis in L929MfasER at concentrations as low as 10(-10)-10(-9) M, while it did so partially in L929MfasTmR at concentrations greater than 10(-7) M. Thus, L929MfasTmR cells were highly susceptible to Tm, but refractory to E2, with 100-1,000 times more tolerance than L929MfasER. These results suggest that the MfasTmR/Tm system would induce apoptosis in the target cells more safely in vivo, working independently of endogenous estrogen.
Asunto(s)
Apoptosis/efectos de los fármacos , Antagonistas de Estrógenos/farmacología , Terapia Genética , Receptores de Estrógenos/genética , Proteínas Recombinantes de Fusión/genética , Tamoxifeno/análogos & derivados , Receptor fas/genética , Animales , Fragmentación del ADN/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Estradiol/farmacología , Ratones , Mutación , Tamoxifeno/farmacologíaRESUMEN
RA shows a variety of actions including the teratogenicity at pharmacological doses, but its physiological roles remain unclear. Recently, receptors for RA, RARs, have been identified and shown to belong to the nuclear receptor superfamily. We introduced a mutation, which was originally identified in the thyroid hormone receptor gene, causing dominantly inherited thyroid hormone resistance, to the equivalent position in RAR, and showed that the mutated RAR demonstrated a dominant-negative phenotypes. We next expressed the mutated RAR specifically in chondrogenic cells in mice. From the analysis of mice phenotypes, we unveiled the chondrogenic cells as a novel vital RA target in skeletal development. The results simultaneously indicated that RA specifies cervical identities through the regulation of homeobox genes.
Asunto(s)
Receptores de Ácido Retinoico/química , Secuencia de Aminoácidos , Animales , Condrocitos , Genes Homeobox , Ratones , Ratones Noqueados , Datos de Secuencia Molecular , Mutación , Osteogénesis/genética , Receptores de Ácido Retinoico/genética , Receptores de Ácido Retinoico/fisiología , TransgenesRESUMEN
The binding of all-trans retinoic acid (ATRA) to the ligand-binding region in the E-domain of retinoic acid receptor-alpha modifies the transcriptional activity of RARalpha protein. ATRA probably induces differentiation of acute promyelocytic leukemia (APL) cells by binding to the E-domain of the RARalpha portion (RARalpha /E-domain) of PML/RARalpha chimeric protein. Therefore, molecular alteration in the RARalpha /E-domain of the chimeric gene is one mechanism by which patients with APL may acquire resistance to ATRA therapy. In this study using reverse transcription-polymerase chain reaction and single-strand conformation polymorphism, DNA segments amplified from the RARalpha /E-domain in fresh APL cells of 23 APL patients (8 males and 15 females from 4 to 76 years of age) were screened for mutations. Of those patients, 3 patients (1 with de novo and 2 with relapse) had clinical resistance to ATRA therapy. We found mutations in the RARalpha /E-domain of PML/RARalpha chimeric gene exclusively in the 2 patients who exhibited ATRA-resistance at relapse, whereas the mutations were not detected at their initial onset. Interestingly, these patients received a prolonged or intermittent administration of ATRA before relapse with ATRA-resistance. The mutations lead to the change of amino acid in the ligand-binding region of RARalpha /E-domain, Arg272Gln, or Met297Leu according to the amino acid sequence of RARalpha, respectively. Further study demonstrated that the in vitro ligand-dependent transcriptional activity of the mutant PML/RARalpha protein was significantly decreased as compared with that of wild-type PML/RARalpha. These findings suggest that mutations in the RARalpha /E-domain of the PML/RARalpha chimeric gene may confer clinical resistance to ATRA therapy in patients with APL.
Asunto(s)
Antineoplásicos/farmacología , Resistencia a Antineoplásicos/genética , Leucemia Promielocítica Aguda/tratamiento farmacológico , Leucemia Promielocítica Aguda/genética , Proteínas de Neoplasias/genética , Proteínas de Fusión Oncogénica/genética , Tretinoina/farmacología , Adolescente , Adulto , Secuencia de Aminoácidos , Antineoplásicos/uso terapéutico , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Mutación , Receptores de Ácido Retinoico/genética , Receptor alfa de Ácido Retinoico , Tretinoina/uso terapéuticoRESUMEN
For cancer gene therapy, it is of primary importance to develop a system to sufficiently and selectively express therapeutic genes in cancer cells. In this study, we showed that an approximately 5.3-kb promoter region of the prostate-specific antigen (PSA) gene can replicate the endogenous expression pattern, although its expression is very weak. We then developed a novel two-step transcriptional activation system in which the PSA promoter drives an artificial transcriptional activator, GAL4-VP16 fusion protein, and it in turn activates transgene expressions under the control of GAL4-responsive elements. By using this system, transgene expressions can be greatly augmented while maintaining prostate-specific expression. Finally, we applied this system to drive an expanded polyglutamine, a potent proapoptotic molecule, to induce apoptosis selectively in PSA-positive prostate cancer cells. This novel system would provide an ideal approach for cancer gene therapy applicable not only to prostate cancer but to other cancers as well.
Asunto(s)
Terapia Genética/métodos , Péptidos/genética , Próstata/metabolismo , Neoplasias de la Próstata/terapia , Apoptosis , Proteínas Fúngicas/genética , Proteínas Fúngicas/metabolismo , Amplificación de Genes , Células HeLa , Humanos , Masculino , Péptidos/metabolismo , Regiones Promotoras Genéticas , Antígeno Prostático Específico , Transactivadores/genética , Transactivadores/metabolismo , Activación Transcripcional , Transgenes , Células Tumorales CultivadasRESUMEN
Skeletal formation is a fundamental element of body patterning and is strictly regulated both temporally and spatially by a variety of molecules. Among these, retinoic acid (RA) has been shown to be involved in normal skeletal development. However, its pleiotropic effects have caused difficulty in identifying its crucial target cells and molecular mechanisms for each effect. Development of cartilage primordia is an important process in defining the skeletal structures. To address the role of RA in skeletal formation, we have generated mice expressing a dominant-negative retinoic acid receptor (RAR) in chondrogenic cells by using the type II collagen alpha1 promoter, and we have analyzed their phenotypes. These mice exhibited small cartilage primordia during development and retarded skeletal formation in both embryonic and postnatal periods. They also showed selective degeneration in their cervical vertebrae combined with homeotic transformations, but not in their extremities. The cervical phenotypes are reminiscent of phenotypes involving homeobox genes. We found that the expression of Hoxa-4 was indeed reduced in the cartilage primordia of cervical vertebrae of embryonic day 12.5 embryos. These observations demonstrate that endogenous RA acts directly on chondrogenic cells to promote skeletal growth in both embryonic and growing periods, and it regulates the proper formation of cervical vertebrae. Furthermore, RA apparently specifies the identities of the cervical vertebrae through the regulation of homeobox genes in the chondrogenic cells. Great similarities of the phenotypes between our mice and reported RAR knockout mice revealed that chondrogenic cells are a principal RA target during complex cascades of skeletal development.
Asunto(s)
Huesos/anomalías , Vértebras Cervicales/anomalías , Condrocitos/metabolismo , Proteínas de Unión al ADN , Receptores de Ácido Retinoico/genética , Animales , Huesos/embriología , Cartílago/embriología , Cartílago/metabolismo , Células Cultivadas , Vértebras Cervicales/embriología , Genotipo , Proteínas de Homeodominio/metabolismo , Hibridación in Situ , Ratones , Ratones Transgénicos , Factores de Transcripción , Tretinoina/antagonistas & inhibidoresRESUMEN
The neurodegenerative diseases Huntington disease, dentatorubropallidoluysian atrophy, spinocerebellar atrophy type 3, and spinal bulbar muscular atrophy are caused by expansion of a polyglutamine tract within their respective gene products. There is increasing evidence that generation of truncated proteins containing an expanded polyglutamine tract may be a key step in the pathogenesis of these disorders. We now report that, similar to huntingtin, atrophin-1, ataxin-3, and the androgen receptor are cleaved in apoptotic extracts. Furthermore, each of these proteins is cleaved by one or more purified caspases, cysteine proteases involved in apoptotic death. The CAG length does not modulate susceptibility to cleavage of any of the full-length proteins. Our results suggest that by generation of truncated polyglutamine-containing proteins, caspase cleavage may represent a common step in the pathogenesis of each of these neurodegenerative diseases.
Asunto(s)
Caspasas , Proteínas del Tejido Nervioso/metabolismo , Enfermedades Neurodegenerativas/genética , Proteínas Nucleares/metabolismo , Péptidos , Serina Endopeptidasas/metabolismo , Repeticiones de Trinucleótidos , Secuencia de Aminoácidos , Apoptosis , Ataxina-3 , Caspasa 1 , Caspasa 3 , Caspasa 7 , Caspasa 8 , Caspasa 9 , Cisteína Endopeptidasas/metabolismo , Humanos , Proteína Huntingtina , Células Jurkat , Cinética , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/genética , Proteínas Nucleares/química , Proteínas Nucleares/genética , Osteosarcoma , Receptores Androgénicos/química , Receptores Androgénicos/metabolismo , Proteínas Represoras , Especificidad por Sustrato , Células Tumorales CultivadasRESUMEN
At present, 8 inherited neurodegenerative disorders (e.g. Huntington disease, Machado-Joseph disease, etc.) are identified to be caused by the polyglutamine-coding CAG triplet expansions in the responsible genes. These disorders commonly demonstrate dominant inheritance, if autosomal, and late onset of their manifestations. Interestingly, the longer expansions result in earlier onset and more severe clinical manifestations. Proteins containing expanded polyglutamine repeats appear to precipitate by self-aggregation, and as a result produce a core disease-related phenotype: neuronal cell death or degeneration. Given that polyglutamine aggregation might be central in neurodegeneration, the parameters that determine the feasibility of the polyglutamines to aggregate would determine the age of onset and the clinical severity. These parameters are postulated to be the concentration and the length of polyglutamines, which is supported by clinical and experimental observations. The stronger neuronal degenerations are always accompanied by the longer polyglutamine stretches and by the higher concentration of the expanded polyglutamines. In other neurodegenerative disorders, such as Alzheimer disease, prion disease, Parkinson disease and amyotrophic lateral sclerosis, precipitation of abnormal proteins is also now considered to play a key role. These observations might lead to the elucidation of universal mechanisms for neurodegeneration and to treatments effective for many neurodegenerative disorders.
Asunto(s)
Enfermedades Neurodegenerativas , Repeticiones de Trinucleótidos , Animales , Apoptosis , Humanos , Ratones , Ratones Transgénicos , Enfermedades Neurodegenerativas/genética , Péptidos/genética , Péptidos/fisiologíaRESUMEN
BACKGROUND: The actions of prostaglandin F2alpha are mediated by a cell-surface receptor (FP), but little is known about the regulation of FP gene expression. To clarify the mechanisms underlying tissue specific transcription of the mouse FP gene, we isolated and characterized mouse genomic DNA clones encoding FP. RESULTS: Structural analysis revealed that the mouse FP gene is composed of three exons and two introns, and spans more than 11 kilobases. By primer extension and PCR analyses, the major transcription start site was identified as a cytosine nucleotide, but additional sites of transcription initiation were found in the ovary. There was no apparent difference in the FP gene transcription initiation site between the ovary, kidney and stomach. Sequence analysis of the putative promoter region showed only two potential SP-1 binding sites, but no other typical well-known consensus sequences. We generated transgenic mice with the potential promoter region of the FP gene connected to the lacZ reporter gene. Northern blot analysis showed that the pattern of expression of the transgene corresponded to that of FP expression, except in the ovary. Upon analysis by in situ hybridization, the lacZ gene transcripts were found to be expressed in the fundic glands in the stomach, and the cortical tubules in the kidney, in which endogenous FP transcripts were also expressed. On the contrary, expression of lacZ transcripts was not detected in the corpora lutea, where the highest expression of FP mRNA was observed. CONCLUSIONS: These studies suggest that a separate control mechanism exists for FP expression in the ovary, distinct from the expression in the stomach and kidney.